Loading
Life sciences · Journal article
Frontiers in Plant Science · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Friedelin (FD) is a pentacyclic triterpenoid with significant pharmacological potential and serves as the biosynthetic precursor to the anti-obesity drug celastrol. Despite its value, FD availability is limited by low natural abundance and the stereochemical complexity of chemical synthesis. This article critically reviews the state-of-the-art in FD research, spanning natural distribution, extraction methodologies, and the molecular basis of its biosynthesis. The structural evolution of friedelin synthases (FDSs), contrasting the mechanisms of multifunctional versus single-function enzymes, was analyzed. Furthermore, a comprehensive roadmap for sustainable production, integrating “Push-Block-Regulate-Store” metabolic engineering strategies with novel insights into transcriptional regulation, was provided. It is proposed that the convergence of AI-driven enzyme design, transporter engineering, and CRISPR-based precision breeding will overcome current yield bottlenecks, enabling the industrial-scale biomanufacturing of FD and its derivatives.